214 related articles for article (PubMed ID: 30266989)
21. Ubiquitination of Rheb governs growth factor-induced mTORC1 activation.
Deng L; Chen L; Zhao L; Xu Y; Peng X; Wang X; Ding L; Jin J; Teng H; Wang Y; Pan W; Yu F; Liao L; Li L; Ge X; Wang P
Cell Res; 2019 Feb; 29(2):136-150. PubMed ID: 30514904
[TBL] [Abstract][Full Text] [Related]
22. TSC-insensitive Rheb mutations induce oncogenic transformation through a combination of constitutively active mTORC1 signalling and proteome remodelling.
Xie J; De Poi SP; Humphrey SJ; Hein LK; Bruning JB; Pan W; Selth LA; Sargeant TJ; Proud CG
Cell Mol Life Sci; 2021 Apr; 78(8):4035-4052. PubMed ID: 33834258
[TBL] [Abstract][Full Text] [Related]
23. A small molecule inhibitor of Rheb selectively targets mTORC1 signaling.
Mahoney SJ; Narayan S; Molz L; Berstler LA; Kang SA; Vlasuk GP; Saiah E
Nat Commun; 2018 Feb; 9(1):548. PubMed ID: 29416044
[TBL] [Abstract][Full Text] [Related]
24. Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC).
Zhang Y; Jia QA; Kadel D; Zhang XF; Zhang QB
Med Sci Monit; 2018 May; 24():2735-2743. PubMed ID: 29720580
[TBL] [Abstract][Full Text] [Related]
25. Methionine controls insulin/mammalian target of rapamycin complex 1 activity by modulating tuberous sclerosis complex 2 stability.
Gen S; Matsumoto Y; Suzuki T; Inoue J; Yamamoto Y
Biochem Biophys Res Commun; 2021 Feb; 541():84-89. PubMed ID: 33482580
[TBL] [Abstract][Full Text] [Related]
26. GL-V9 exerts anti-T cell malignancies effects via promoting lysosome-dependent AKT1 degradation and activating AKT1/FOXO3A/BIM axis.
Hu P; Li H; Yu X; Liu X; Wang X; Qing Y; Wang Z; Wang H; Zhu M; Xu J; Tan R; Guo Q; Hui H
Free Radic Biol Med; 2019 Dec; 145():237-249. PubMed ID: 31560953
[TBL] [Abstract][Full Text] [Related]
27. Fisetin regulates obesity by targeting mTORC1 signaling.
Jung CH; Kim H; Ahn J; Jeon TI; Lee DH; Ha TY
J Nutr Biochem; 2013 Aug; 24(8):1547-54. PubMed ID: 23517912
[TBL] [Abstract][Full Text] [Related]
28. MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia.
Canté-Barrett K; Spijkers-Hagelstein JA; Buijs-Gladdines JG; Uitdehaag JC; Smits WK; van der Zwet J; Buijsman RC; Zaman GJ; Pieters R; Meijerink JP
Leukemia; 2016 Sep; 30(9):1832-43. PubMed ID: 27174491
[TBL] [Abstract][Full Text] [Related]
29. TSC1 and DEPDC5 regulate HIV-1 latency through the mTOR signaling pathway.
Jin S; Liao Q; Chen J; Zhang L; He Q; Zhu H; Zhang X; Xu J
Emerg Microbes Infect; 2018 Aug; 7(1):138. PubMed ID: 30087333
[TBL] [Abstract][Full Text] [Related]
30. Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells.
Barata JT; Silva A; Brandao JG; Nadler LM; Cardoso AA; Boussiotis VA
J Exp Med; 2004 Sep; 200(5):659-69. PubMed ID: 15353558
[TBL] [Abstract][Full Text] [Related]
31. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
[TBL] [Abstract][Full Text] [Related]
32. CBAP promotes thymocyte negative selection by facilitating T-cell receptor proximal signaling.
Ho KC; Chiang YJ; Lai AC; Liao NS; Chang YJ; Yang-Yen HF; Yen JJ
Cell Death Dis; 2014 Nov; 5(11):e1518. PubMed ID: 25393474
[TBL] [Abstract][Full Text] [Related]
33. IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes.
Marzec M; Liu X; Kasprzycka M; Witkiewicz A; Raghunath PN; El-Salem M; Robertson E; Odum N; Wasik MA
Blood; 2008 Feb; 111(4):2181-9. PubMed ID: 18025151
[TBL] [Abstract][Full Text] [Related]
34. [The Mechanism of Combination using mTORC1/2 Inhibitor and Imatinib to Suppress Cell Proliferation of Ph
Wu JH; Shi FF; Gong YP; Shi R
Sichuan Da Xue Xue Bao Yi Xue Ban; 2017 Mar; 48(2):216-220. PubMed ID: 28612529
[TBL] [Abstract][Full Text] [Related]
35. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
36. TSC2 regulates microRNA biogenesis via mTORC1 and GSK3β.
Ogórek B; Lam HC; Khabibullin D; Liu HJ; Nijmeh J; Triboulet R; Kwiatkowski DJ; Gregory RI; Henske EP
Hum Mol Genet; 2018 May; 27(9):1654-1663. PubMed ID: 29509898
[TBL] [Abstract][Full Text] [Related]
37. The antileukemia roles of PP242 alone or in combination with daunorubicin in acute leukemia.
Shi F; Yang X; Gong Y; Shi R; Yang X; Naren D; Wu J
Anticancer Drugs; 2015 Apr; 26(4):410-21. PubMed ID: 25535978
[TBL] [Abstract][Full Text] [Related]
38. Single serine on TSC2 exerts biased control over mTORC1 activation mediated by ERK1/2 but not Akt.
Dunkerly-Eyring BL; Pan S; Pinilla-Vera M; McKoy D; Mishra S; Grajeda Martinez MI; Oeing CU; Ranek MJ; Kass DA
Life Sci Alliance; 2022 Jun; 5(6):. PubMed ID: 35288456
[TBL] [Abstract][Full Text] [Related]
39. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer.
Hampsch RA; Shee K; Bates D; Lewis LD; Désiré L; Leblond B; Demidenko E; Stefan K; Huang YH; Miller TW
Oncotarget; 2017 Mar; 8(13):21806-21817. PubMed ID: 28423521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
